Onderneming NeuroBo Pharmaceuticals, Inc.
Aandelen
NRBO
US64132R4048
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,8 USD | +0,53% | +17,65% | +2,80% |
Vakgebied
Aantal werknemers: 8
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 09-07-21 |
Director of Finance/CFO | 66 | 27-10-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
D. Strickland
BRD | Director/Board Member | 77 | 27-01-22 |
Andrew Koven
CHM | Chairman | 66 | 09-07-21 |
Mark Glickman
BRD | Director/Board Member | 58 | 11-05-23 |
Michael Salsbury
BRD | Director/Board Member | 74 | 31-12-19 |
Jason Groves
BRD | Director/Board Member | 52 | 31-12-19 |
James Tursi
BRD | Director/Board Member | 59 | 01/11 |
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 09-07-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 4 906 002 | 1 880 689 ( 38,33 %) | 0 | 38,33 % |
Bedrijfsgegevens
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue Suite 210
02138, Cambridge
+
http://www.neurobopharma.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,80% | 18,54 mln. | |
+9,15% | 105 mld. | |
-1,08% | 104 mld. | |
+5,79% | 22,94 mld. | |
-11,55% | 22,34 mld. | |
-7,01% | 19,25 mld. | |
-37,08% | 17,08 mld. | |
-9,91% | 16,96 mld. | |
+7,55% | 14,16 mld. | |
+40,04% | 12,63 mld. |
- Beurs
- Aandelen
- Koers NRBO
- Onderneming NeuroBo Pharmaceuticals, Inc.